Ghana has approved the world’s first malaria drug for newborns, marking a breakthrough in infant care. But as rollout nears, US funding cuts are hurting promotional campaigns for the drug. The lack of money is also freezing critical research — threatening long-term progress in the fight against the disease. Ridwan Karim Dini-Osman has the story.

This story was produced with support from the Pulitzer Center on Crisis Reporting.